Christopher Benecchi - 13 Feb 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Reporting relationship: Chief Operating Officer
Issuer ticker: SAGE
Reported as of: 13 Feb 2025
Net transaction value: -$5,902
SEC form: 4
Accepted by SEC: 14 Feb 2025, 16:27:04 UTC
Prior SEC filing: 21 Jan 2025
Next SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: Brandon Marsh, attorney in fact for Christopher Benecchi

Key filing fact

Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 14 Feb 2025.

Key facts

This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Feb 2025, 16:27.

Change

Previous filing in this sequence was filed on 21 Jan 2025.
Current net transaction value: -$5,902.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SAGE transaction

Common Stock

Tax liability

Transaction value: $5,902
Shares: -822
Change %: -1.8%
Price: $7.18
Shares after: 43,915
Date: 13 Feb 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On February 13, 2025, the reporting person vested 3,375 shares of time-based restricted stock units (RSUs) granted on February 13, 2024 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.